Reduced intensity allogeneic hematopoietic cell transplantation (HCT) is an effective salvage treatment strategy in patients with follicular lymphoma.
Induction therapy with lenalidomide plus rituximab may result in control that is comparable to rituximab plus chemotherapy for the initial treatment.
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.
Changes in how follicular lymphoma is managed have led to substantial improvement in prognosis and over all survival for patients with the disease.
Vaccines and monoclonal antibodies are promising new treatments for patients with follicular lymphoma.
Compared with rituximab, an initial watch-and-wait strategy is not detrimental in select patients.
High-dose chemotherapy combined with autologous stem cell transplantation did not improve overall survival in previously untreated adult patients with follicular lymphoma.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|